Cannabis market intelligence
Decision-grade intelligence
for global cannabis.
Analyst-curated intelligence for your cannabis business. We turn primary sources, market research and proprietary datasets into structured, decision-grade intelligence.
120+countries covered1,000+companies tracked40+updated datasets420+sources monitored
125+countries covered1,050+companies tracked50+market databases450+sources monitored
Trusted by more than fifty organisations across five continents since 2018
Published intelligence
Research that moves markets.
Data-driven analysis built from the same primary-source intelligence that powers Decide.
United Kingdom · 8 Oct 2026
UK flower gets 35% stronger — while its price premium narrows
Average THC 18.4% → 24.9% since 2022 while a gram moved only £6.13 → £6.59, so THC costs 21% less per mg
Read →
Denmark · 30 Sep 2026
Denmark's medical pilot ends on a record 22,410 prescriptions
Prescriptions up 64% in 2025 for 2,465 patients, now filling 9.1 a year each — as the scheme turns permanent
Read →
Spain · 23 Sep 2026
Spain ships tonnes of cannabis abroad — its patients can reach two products
25,730 kg imported in six months, more than it exports for the first time — while just 2 of 13 preparations are registered
Read →
Netherlands · 15 Sep 2026
Dutch coffeeshops triple their range — while hash prices go the other way
25 → 78 products per shop against 27 → 36 in control towns — while hash menu prices rose 81%
Read →
Portugal · 2 Sep 2026
Portugal exports 66 tonnes in six months — as its operator base shrinks
66,305 kg shipped in H1 2026 — 83% of a record year — while licensed entities fell 49 → 43
Read →
Australia · 20 Aug 2026
Australia imports a record 81 tonnes — as its market contracts for the first time
81.1t imported and 55.3t grown at home — while units supplied fell 28.6% in H2 2025
Read →
Our analysis is cited in the press — and presented on stage
Live trackers
Six of our trackers, open to everyone and updated as the data lands.
Pick a market or a tracker to see where it stands today. Every chart below is drawn from the records we keep current in Decide, and every one of them opens the full tracker behind it.
cannamonitor.com/uk/cannamonitor.com/germany/cannamonitor.com/spain/cannamonitor.com/australia/cannamonitor.com/deal-tracker/cannamonitor.com/clinical-pipeline/Tracking six datasets
United Kingdom · NHSBSA dispensing · England
England dispensed 1.77m items of medical cannabis in 2025, and no single supplier controls the shelf any more.
Latest · Report · Sep 2026Open the UK tracker →
Items dispensed in England, 20251.77m↑ +165% on 2024England only and under-reported, so read it as a floor.↗Value has grown 24× since 2021£m at August 2026 list prices↗Two-thirds of 2025 imports reached a patientFlower, tonnes · imported (UK) vs dispensed (England)↗Curaleaf’s share fell from 61% to 25% in two years% of items · Curaleaf vs the top five operators↗Canada grows half of the flower England dispenses% of 2025 flower, by country of cultivation↗Flower THC climbed from 18.4% to 24.9%Volume-weighted THC of dispensed flower, 2022 Q1 – 2025 Q4↗Alternaleaf overtook Releaf for clinic traffic in May 2026% of tracked clinic web traffic · Sep 2025 – Aug 2026, Oct–Nov not captured↗The strongest flower took the deepest price cutsLike-for-like list-price change by THC band, Oct 2025 → Aug 2026↗
NHSBSA dispensing records (England only, a floor for the UK), Home Office import licensing, dated formulary snapshots and SimilarWeb clinic traffic. From our UK Medical Cannabis Market Report, September 2026. Read 8 Oct 2026.
Germany · BfArM · GKV · regulatory tracker
Germany imported 205 tonnes in 2025, then posted its first quarterly decline on record.
Latest · BfArM · Q1 2026Open the Germany tracker →
Flower imported into Germany, 2025205 t↑ +182% on 2024BfArM annual series, 2018–2025.↗Imports fell 17% in Q1 2026, the first decline on recordTonnes imported per quarter, Q1 2024 – Q1 2026↗Canada and Portugal supply nearly three-quartersTonnes imported in 2025, by origin↗Patients grew from ~250k to ~900k after legalisationThousands of patients · 2027–28 are our projections↗One platform draws 39% of telemedicine trafficMonthly visits, June 2026 · top six of 42 tracked↗Retail flower is down 52% in 26 months€ per gram, Cannamonitor reconciled estimate↗€205M of reimbursement is struck or gatedGKV spend 2025, €M · gold struck, teal gated, green kept↗Momentum is restrictive where the money isRegulatory momentum score, −100 to +100 · selected stories↗
BfArM quarterly import releases, GKV-Gamsi reimbursement, Cannamonitor retail price reconciliation and patient projections, SimilarWeb telemedicine traffic and our German regulatory tracker. Read 8 Oct 2026.
Spain · AEMPS · importing-country records
Spain grows medical cannabis for export, and at home only hospital pharmacies may dispense it.
Latest · Updated · Aug 2026Open the Spain tracker →
Arriving in the UK and Germany from Spain, 20258,211 kg↑ 24× the 2020 levelRecorded by the importing countries, a record year.↗Germany overtook the UK as Spain’s buyer in 2025kg recorded arriving from Spain, by destination↗Spain re-exports far more than it is authorised to growTonnes · authorised production vs exports, 2018–2024 (AEMPS / INCB)↗22,231 pharmacies, and none of them may dispense itUnder RD 903/2025 hospital pharmacy services are the whole legal channel353hospital services can22,231community pharmacies cannot↗22 cultivation authorisations across 20 entitiesAEMPS cultivation register, 22 July 2026↗Lifetime use nearly doubled to 44%; last-year use finally moved% of adults aged 15–64, OEDA 1997–2024↗Seized resin is now 30% THC, up from 12%Mean THC of analysed seizures, OEDA 2002–2021↗The decree opened a door that is barely ajarReal Decreto 903/2025, from signature to supply
- Oct 2025Decree published: hospital pharmacies only
- Jan 2026Monograph: oral solutions only, no flower
- Jan 2026Laboratory register opens
- Mar 2026Two laboratories registered
UK Home Office and BfArM records of arrivals from Spain, AEMPS / INCB production and trade, the AEMPS cultivation register, CGCOF pharmacy census, OEDA surveys and seizure analysis, and RD 903/2025. Read 8 Oct 2026.
Australia · ODC · TGA · Statistics Canada
Australia imported a record 81 tonnes in 2025, while units supplied to patients fell 28.6% in a single half.
Latest · TGA · H2 2025Open the Australia tracker →
Flower imported into Australia, 202581.1 t↑ +4.8% on 2024A record year, from ODC import records.↗Home cultivation grew 30%, far faster than importsTonnes of flower · imported vs grown in Australia↗Thailand took a quarter of imports in a single year% of 2025 flower imports, by origin↗Units supplied fell 28.6% in one halfMillions of units supplied by sponsors, 2025↗One pathway now carries 89% of the marketSpecial Access Scheme share of units supplied, H2 2021 – H2 2025↗25–30% THC is the new core of the market% of flower units by THC band↗Canada cut its Australian price 41% in a yearCA$ per kg declared into each market, H1 2025 vs H1 2026↗Alternaleaf leads Australian clinic trafficTracked monthly visits, May 2026 · top six↗
ODC import and production records, TGA sponsor supply returns (units supplied, not patients), Statistics Canada declared export values and SimilarWeb clinic traffic, May 2026. Read 8 Oct 2026.
M&A and funding tracker · 2017 to today
2026 has already logged more cannabis deals than all of 2025, with a quarter still to run.
Live · Last deal · 5 Oct 2026Open the M&A tracker →
Cannabis deals tracked, 2017 to today640+$40bn+ in disclosed valueLast deal logged 5 October 2026.↗2026 has already passed 2025’s full-year totalCannabis deals per year · 2026 to 5 October↗Up 51% on the same point last yearDeals logged 1 January – 5 October, each year↗Acquisitions are half of all dealsDeals by type · untyped records excluded↗Four markets carry most of the deal flowDeals tagged per market · one deal can carry several↗Manufacturing and cultivation change hands mostDeals tagged per supply-chain layer↗Latest deals loggedNewest first, as they land in the tracker
- Vireo Growth closes a US$60m real-estate loanUSDebt
- AYR Wellness hands its Ohio operations to its noteholdersUSAsset sale
- Griffin bids for bankrupt grow-supply distributor BFG SupplyUSAsset sale
- IM Cannabis sells its European arm, including AdjupharmIL · DEAsset sale
Every cannabis deal in our M&A and funding tracker, each linked to its source. Tags exceed deals because one deal can carry several markets or layers. Read 8 Oct 2026.
Clinical trials · 13 registries · 48 countries
Cannabinoid trial starts hit a record in 2025, yet only 16% of the pipeline is Phase III or IV.
Live · Last trial · 5 Oct 2026Open the clinical tracker →
Cannabinoid clinical trials on record2,300+13 registries · 48 countriesLast trial added 5 October 2026.↗177 trials started in 2025, a recordTrials by registered start year · 2026 so far, lighter↗Only 16% of trials are Phase III or IVTrials by phase↗Pain and neurology lead the late-phase workTrials per condition group · all vs Phase III–IV↗Industry pays for over a third of late-phase workIndustry-funded share of trials, 24 Aug 2026 analysis↗Whole-plant extracts dominate what gets testedTrials by compound class · single-class records↗429 trials are recruiting patients right nowOf the 2,300+ on record429recruiting729completed↗The US hosts more trials than the next ten countriesTrials per country, 24 Aug 2026 analysis↗
One record per trial, merged from 13 registries and deduplicated. Funder and country splits come from the 24 Aug 2026 analysis; everything else is today’s count. Read 8 Oct 2026.
Latest
InsightUK flower gets 35% stronger while its price premium narrowsM&AVireo Growth closes a US$60m real-estate loanTrialsJohns Hopkins starts a Phase II of Epidiolex in presymptomatic Sturge-Weber syndromeM&AAYR Wellness hands its Ohio operations to its noteholdersInsightDenmark’s medical pilot ends on a record 22,410 prescriptionsM&AIM Cannabis closes the sale of its European arm, including AdjupharmTrialsPleoPharma’s PP-01 cuts cannabis-withdrawal severity in a Phase 1b/2aInsightSpain ships tonnes of cannabis abroad, while its patients can reach two products
Each tracker is one slice of Decide, where the same records sit connected to every other market we cover.See how Decide connects them →
What we fix
Cannabis data is abundant. Decision-grade cannabis data is not.
Anyone can find a number. Knowing what it counts, what it leaves out and whether it agrees with the three sources that contradict it is the work, and it is what you are paying for.
✕Tap each problem to see how we fix itof 5 fixed
Fix all 5 to see the differenceAll five fixed. That is what working in Decide feels like.See how Decide works →
Free · every month
The Monthly Intelligence Brief.
Every month our analysts read what changed in between 38 and 52 markets and send you the moves that matter, sorted into the three questions you actually ask. It is read by 3,500+ people who move this market.
Swipe for all three →
RegulationReforms, licensing and politics“Who changed the rules this month, and who is about to?”
For regulatory affairs, market access and policy teams
What every issue gives you↑
In every issueReforms and proposalsLicensingCourt rulings
You’ll use it toCatch a rule change earlyBrief your boardTime a filing
MarketSales, trade, deals and financials“Where is the money moving, and who is moving it?”
For commercial, business development and investment teams
What every issue gives you↑
In every issueSales and pricingTrade flowsDeals and results
You’ll use it toSize a marketTrack a competitorFind a partner
ScienceTrials, R&D and surveys“What does the evidence actually say?”
For medical affairs, R&D and product teams
What every issue gives you↑
In every issueClinical trialsR&DPopulation surveys
You’ll use it toFollow a pipelineCheck a claimSpot a new indication
Browse every edition →
🔒
The full brief opens to everyone one month after it ships.Essentials and Decide subscribers read the full country-by-country edition on the day it lands.Compare plans →
Subscribe
Unlock the insights trusted by 3,500+ cannabis leaders
Subscribers receive each issue on the day it ships. Everyone else waits a month.
Join 3,500+ cannabis leaders. No spam, unsubscribe in one click.
The platform · Decide
Everything connects back to a country and a company.
Countries and companies sit at the core of Decide, and every deal, filing, trial and rule change is tied back to them, so one click takes you from a German reimbursement ruling to the supplier it hits. Pick a module to open a slice of what landed in it in August.
Pick a module
CountriesGermany, one of 125+ market profiles
Every market on one page: demand, supply, regulation and the companies inside it, already joined up.
Linked toRegulatoryCompaniesClinical trials
Open it in Decide →decide.cannamonitor.com › Countries › GermanyLive
€1.15bnmedical market, 2026
67.6 tQ1 2026 imports, revised up 33%
~¾of market value now self-pay
- KBV reverses its reimbursement guidance in twelve days
- Curaleaf bids for Aurora, the largest EU-GMP supplier into Germany
- Nature Medicine RCT: dronabinol cuts PTSD nightmares
CompaniesAurora Cannabis, one of 1,050+ company profiles
One page per operator, with its deals, results, licences and news linked as they happen.
Linked toM&AEarningsCountries
Open it in Decide →decide.cannamonitor.com › Companies › Aurora CannabisLive
A
Aurora Cannabis🇨🇦 Canada · the largest EU-GMP supplier into Germany
- M&ACuraleaf’s US$236m unsolicited bid18 Aug 2026
- EarningsInternational medical up 17%Fiscal Q1 2027
- CountriesUK pharmacy and import licence for £2.1mAug 2026
- NewsBoard advises shareholders to take no actionBid open
RegulatoryA living layer, 270+ regulatory briefs
Each situation is followed as it develops, so you see the reversal, not just the first headline.
Linked toCountriesCompaniesNews
Open it in Decide →decide.cannamonitor.com › Regulatory › Germany › ReimbursementLive
~65,000patients affected
12 daysfrom position to reversal
2finished medicines that qualify
- KBV and GKV-Spitzenverband limit finished-medicine priority to licensed indications
- KBV reverses: a finished medicine first in the six-month trial period, even off-label
- G-BA opens its consultation on flower reimbursement
Market dataStructured datasets, 50+ market databases
Official and aggregated sources, cleaned into datasets that compare across countries and over time.
Linked toCountriesCompaniesRegulatory
Open it in Decide →decide.cannamonitor.com › Market data › Canada › LicencesLive
900federal licences, end Aug 2026
45new licences, Jan–Aug
56revocations, Jan–Aug
Licences by class, end of August 2026
NewsClassified as it lands, 10,000+ items
Vetted sources only, each item tagged to the market, company and deal it touches.
Linked toCountriesCompaniesRegulatory
Open it in Decide →decide.cannamonitor.com › News › August 2026Live
- Recurring patients pass one million as ANVISA’s cultivation rules take forceBrazil
- Pharmacy sales reach 4.5 tonnes in H1 as home cultivation is rejectedPoland
- 16 hemp and CBD measures ordered after a 63% violation rateCzechia
- A medical-only bill is drafted as the fraud probe widens to 20 clinicsThailand
EarningsComparable results, 600+ filings
Results standardised for currency, period and definition, so you can line operators up against each other.
Linked toCompaniesM&ACountries
Open it in Decide →decide.cannamonitor.com › Earnings › Who is selling abroadLive
CompanyLineLatestYoYVillage FarmsExportsUS$20.9m+74%DecibelInternationalC$10.6m+72%CronosNet revenueUS$53.0m+58%STENOCARENet salesDKK 4.0m+33%
M&A & FundingEvery deal, source-linked, 640+ deals
Bids, acquisitions, disposals and grants, each linked to the buyer, the target and the market.
Linked toCompaniesEarningsCountries
Open it in Decide →decide.cannamonitor.com › M&A & Funding › August 2026Live
- Curaleaf launches a US$236m unsolicited bid for AuroraBid
- Aurora buys a UK pharmacy and import licence for £2.1mAcquisition
- Cannect buys digital pharmacy Pill in BrazilAcquisition
- IM Cannabis agrees to sell its European assetsDisposal
Clinical trialsEvidence, standardised, 2,300+ trials
Trials matched to sponsor, product and indication, including the ones that disagree with each other.
Linked toCompaniesCountriesRegulatory
Open it in Decide →decide.cannamonitor.com › Clinical trials › August 2026Live
ProductIndicationResult or stageDronabinolPTSD nightmaresRCT: fewer, milderPP-01Cannabis use disorderPhase 3 fundedNTI164AutismRCT: beat placeboCBD-rich oilAutismRCT: no advantage
Testimonials
Trusted where the decisions get made.
Operators, investors, founders and analysts who run their calls on our data.
“The report is amazing. Congrats for being the most loved and hated person in cannabis at the same time.”
“The best reports on the market. The depth, concise insights, data visualisation — all of this make it #1.”
“Cannamonitor is the best source of international cannabis activity out there!”
“The report adds great value to the sector! Many thanks for your dedication and analysis.”
“Cannamonitor lay out a wide range of services that were exactly as requested and beyond. The professionalism in the approach was second only to the quality of commercial leads we generated as a result.”
“The quality of the information received was very specific after an in-depth analysis of the company’s strategy. Most positive was the extensive knowledge in the cannabis industry.”
“We acquired a very high depth of knowledge in a relatively small amount of time. The presentation was detailed and structured with comprehensive and attractive visuals.”
Where to start
Four ways to work with us.
Start free, and move up when the question gets bigger.
Monthly Brief
Free
One email a month. What moved in regulation, markets and science.
- ✓Monthly brief, one month after publication
- ✓Free insight articles
- ✕Same-day access to the brief
- ✕Structured datasets
- ✕Company & country profiles
Essentials
€142/yearor €14.2 a month
Track the whole market. For a single professional staying current.
- ✓Brief on publication day
- ✓Full insight archive
- ✓Curated news & regulatory feed
- ✕Structured datasets & exports
- ✕Company & country profiles
Most popular
Decide
€1,420/year+ €420 a year per extra seat
The full connected graph, every module. For a professional making executive decisions.
- ✓Everything in Essentials
- ✓All 12 connected modules
- ✓50+ market databases, filter & export
- ✓Company, country, deal & trial profiles
- ✕API, SSO and bespoke work
Enterprise & advisory
Quoted
Multi-seat access, API, bespoke monitoring and commissioned research.
- ✓Everything in Decide
- ✓Multi-seat & SSO
- ✓API and data delivery
- ✓Tailored taxonomies & alerts
- ✓Commissioned research & advisory
Track the market with the brief. Graduate to Decide when you’re ready.
Free, monthly, and read by 3,500+ people who move this market.